Michaela Pewarski - Stagwell VP Relations
| STGW Stock | USD 7.86 0.05 0.63% |
Insider
Michaela Pewarski is VP Relations of Stagwell
| Address | One World Trade Center, New York, NY, United States, 10007 |
| Phone | 646 429 1800 |
| Web | https://www.stagwellglobal.com |
Stagwell Management Efficiency
The company has return on total asset (ROA) of 0.0201 % which means that it generated a profit of $0.0201 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0728 %, meaning that it created $0.0728 on every $100 dollars invested by stockholders. Stagwell's management efficiency ratios could be used to measure how well Stagwell manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stagwell's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to climb to 0.000037 in 2024, whereas Return On Capital Employed is likely to drop 0.04 in 2024. At this time, Stagwell's Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Schmidt | ADC Therapeutics SA | 43 | |
| Robert Samuels | Comtech Telecommunications Corp | N/A | |
| Jennie Reilly | Comtech Telecommunications Corp | N/A | |
| Jacques Theurillat | ADC Therapeutics SA | 62 | |
| Lajuana Johnson | Comtech Telecommunications Corp | N/A | |
| Leo Kulmaczewski | Belden Inc | 58 | |
| Susan Romanus | ADC Therapeutics SA | 59 | |
| Anshuman Mehrotra | Belden Inc | 53 | |
| Mitchell Walorski | CTS Corporation | N/A | |
| Ronan Kelly | ADTRAN Inc | N/A | |
| Michael Mulkerrin | ADC Therapeutics SA | 69 | |
| Colonel Atcheson | Comtech Telecommunications Corp | N/A | |
| Thomas Rinderknecht | ADC Therapeutics SA | 67 | |
| Peter Greaney | ADC Therapeutics SA | 41 | |
| Richard Onyett | ADC Therapeutics SA | 73 | |
| Dr DPHIL | ADC Therapeutics SA | 65 | |
| Stephen Evansfreke | ADC Therapeutics SA | 68 | |
| Lisa Skelton | ADC Therapeutics SA | 53 | |
| MS MBA | ADC Therapeutics SA | 51 | |
| Joseph Camardo | ADC Therapeutics SA | 71 | |
| Amanda Hamilton | ADC Therapeutics SA | N/A | |
Management Performance
| Return On Equity | 0.0728 | ||||
| Return On Asset | 0.0201 |
Stagwell Leadership Team
Elected by the shareholders, the Stagwell's board of directors comprises two types of representatives: Stagwell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stagwell. The board's role is to monitor Stagwell's management team and ensure that shareholders' interests are well served. Stagwell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stagwell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jay Leveton, President | ||
| Ryan Greene, Chief Officer | ||
| David Sable, Executive Chair | ||
| Frank Lanuto, Chief Officer | ||
| David Kwon, Senior Strategy | ||
| Mark Penn, Chairman CEO | ||
| Stephanie Howley, Chief Officer | ||
| Michaela Pewarski, VP Relations | ||
| Beth Sidhu, Chief Officer | ||
| Shannon Pruitt, Global Officer | ||
| Jason Reid, Executive Officer | ||
| Mike Pienaar, Risk, Audit | ||
| Merrill Raman, Chief Officer | ||
| Ryan Linder, Executive CMO | ||
| Peter McElligott, General Counsel | ||
| Vincenzo DiMaggio, Senior Officer | ||
| Ben Allanson, Director Relations |
Stagwell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stagwell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0728 | ||||
| Return On Asset | 0.0201 | ||||
| Profit Margin | 0.0001 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 2.51 B | ||||
| Shares Outstanding | 111.55 M | ||||
| Shares Owned By Insiders | 4.18 % | ||||
| Shares Owned By Institutions | 96.02 % | ||||
| Number Of Shares Shorted | 3.97 M | ||||
| Price To Earning | 239.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Stagwell Stock Analysis
When running Stagwell's price analysis, check to measure Stagwell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stagwell is operating at the current time. Most of Stagwell's value examination focuses on studying past and present price action to predict the probability of Stagwell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stagwell's price. Additionally, you may evaluate how the addition of Stagwell to your portfolios can decrease your overall portfolio volatility.